摘要
钠-葡萄糖协同转运蛋白2(SGLT-2)是一种跨膜蛋白,主要分布在肾脏近曲小管,将葡萄糖从肾小管液转运入肾小管细胞内,约占肾脏重吸收葡萄糖的90%。SGLT-2抑制剂是治疗糖尿病的新药,可降低SGLT-2活性,减少肾脏对葡萄糖的重吸收量,增加尿糖排出,从而降低血糖。已有的临床试验表明SGLT-2抑制剂dapagliflozin治疗糖尿病有效且安全,患者耐受性良好。SGLT-2抑制剂很可能是未来糖尿病治疗的一个新的突破口。
Sodium-glucose transporter 2 （SGLT-2） is a transmembrane protein, mainly in the renal proximal tubule. Glucose is completely reabsorbed from the tubular fluid into the tubular cells by SGLT-2, and do not appear in the urine even though large amounts are filtered by the glomerular capillaries. SGLT-2 is responsible for nearly 90% renal reabsorption of glucose. SGLT-2 inhibitor, a new oral antidiabetic drug, can reduce blood glucose through decreasing the activity of SGLT-2 and block the reabsorption of glucose. Clinical trials indicated that SGLT-2 inhibitor （dapagliflozin） was effective and safe in diabetic patients and was well tolerated. SGLT-2 inhibitor is likely to be the future treatment of diabetes, a new breakthrough.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2011年第6期403-406,共4页
Chinese Journal of New Drugs and Clinical Remedies
